Kobayashi Taira, Hamamoto Masaki, Okazaki Takanobu, Hasegawa Misa, Fujiwara Takashi, Takahashi Shinya
Department of Cardiovascular Surgery, JA Hiroshima General Hospital, Hiroshima, Japan.
Department of Reconstructive and Plastic Surgery, JA Hiroshima General Hospital, Hiroshima, Japan.
Vascular. 2021 Dec;29(6):905-912. doi: 10.1177/1708538120981224. Epub 2020 Dec 21.
The purpose of this study was to evaluate the results of combining superficial femoral artery endovascular therapy with distal bypass originating from the popliteal artery as a method of lower extremity revascularization in patients with chronic limb-threatening ischemia.
The records of patients undergoing combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass for chronic limb-threatening ischemia from January 2014 to April 2020 at a single institution were retrospectively reviewed. The patients' background, operative details, and long-term outcomes were analyzed.
Fifty-two popliteal-to-distal bypasses with superficial femoral artery endovascular therapy were performed in 49 patients (33 men; mean age, 76 ± 9 years; diabetes mellitus, 80%; end-stage renal disease with hemodialysis, 47%). The Trans-Atlantic Inter-Society Consensus II classification of superficial femoral artery-popliteal lesion was "A" in 8 (15%) patients, "B" in 14 (27%) patients, "C" in 24 (46%) patients, and "D" in 6 (12%) patients. The intervention for superficial femoral artery lesions was plain old balloon angioplasty in 4 patients, self-expandable nitinol stent in 15 patients, drug-coated balloon in 18 patients, drug-eluting stent in 4 patients, stent graft in 10 patients, and interwoven nitinol stent in 1 patient. Distal bypass originated from the above-knee popliteal artery in 9 (17%) limbs and the below-knee popliteal artery in 43 (83%) limbs. The most common outflow artery was the posterior tibial artery (44%). The mean follow-up period was 17 ± 17 months. The primary and secondary patency of the graft was 44% and 72%, respectively, at 1 year and 39% and 72%, respectively, at 3 years. Primary patency and freedom from clinical-driven target lesion revascularization of superficial femoral artery endovascular therapy lesions were 85% and 90%, respectively, at 1 year and 63% and 75%, respectively, at 3 years. Limb salvage was 97% at 1 year and 92% at 3 years. Wound healing was 67% at 6 months and 83% at 12 months.
Combined superficial femoral artery endovascular therapy with popliteal-to-distal bypass may be a promising approach for patients with chronic limb-threatening ischemia because of durable patency, acceptable wound healing, and good limb salvage.
本研究旨在评估股浅动脉腔内治疗联合源自腘动脉的远端旁路移植术作为慢性肢体威胁性缺血患者下肢血运重建方法的效果。
回顾性分析2014年1月至2020年4月在单一机构接受股浅动脉腔内治疗联合腘动脉至远端旁路移植术治疗慢性肢体威胁性缺血患者的病历。分析患者的背景、手术细节和长期预后。
49例患者(33例男性;平均年龄76±9岁;糖尿病患者占80%;接受血液透析的终末期肾病患者占47%)进行了52例股浅动脉腔内治疗联合腘动脉至远端旁路移植术。根据跨大西洋两岸血管外科学会(Trans-Atlantic Inter-Society Consensus,TASC)II分类,股浅动脉-腘动脉病变中,8例(15%)为“A”型,14例(27%)为“B”型,24例(46%)为“C”型,6例(12%)为“D”型。4例患者对股浅动脉病变采用单纯球囊血管成形术,15例采用自膨式镍钛合金支架,18例采用药物涂层球囊,4例采用药物洗脱支架,10例采用覆膜支架,1例采用编织镍钛合金支架。9例(17%)肢体的远端旁路移植源自腘动脉上段,43例(83%)源自腘动脉下段。最常见的流出道动脉是胫后动脉(44%)。平均随访期为17±17个月。1年时移植物的一期通畅率和二期通畅率分别为44%和72%,3年时分别为39%和72%。股浅动脉腔内治疗病变的1年一期通畅率和免于临床驱动靶病变血运重建率分别为85%和90%,3年时分别为63%和75%。1年时肢体挽救率为97%,3年时为92%。6个月时伤口愈合率为67%,12个月时为83%。
股浅动脉腔内治疗联合腘动脉至远端旁路移植术对于慢性肢体威胁性缺血患者可能是一种有前景的方法,因为其具有持久的通畅率、可接受的伤口愈合情况和良好的肢体挽救率。